cyrilzakka/clinical-trials huggingface dataset:
Three Dimensional Evaluation of Apexogenesis of Immature Young Permanent Teeth With Different Endodontic Material

Randomized Clinical Trial using Three Dimensional Evaluation of Apexogensis of immature young permanent teeth with Different Endodontic Tri-calcium Silicate-Based Putties

Treatment of immature permanent teeth has always been challenging in endodontics, not only because of their wide-open root apices but also because of the thin underdeveloped dentinal walls.Apexogenesis falls under the category of vital pulp therapy (VPT) procedure to maintain pulp vitality, induce dentin bridge formation and encourage continued root maturation.

To overcome the drawbacks of tricalcium silicate-based cements, a range of bioactive endodontic cements have been developed.

EndoSequence BC RRM-Fast Set Putty and NeoPutty (NuSmile, Houston, TX, USA) are the two materials evaluated in this study.

Eligibility Criteria:
Inclusion Criteria:

* First permanent molar with pulpitis.
* Sufficient tooth structure for placing rubber dam.
* Presence of open apex.
* Short root length.

Exclusion Criteria:

* Insufficient tooth structure that need post and core.
* Presence of swelling.
* Presence of sinus tract.
* Presence of root fracture.
* Presence of root crack.
* Presence of external or internal root resorption.
* Presence of periapical pathosis.
* Presence of root calcification.
Single Anastomosis Sleeve Jejunal (SAS-J) Bypass

The purpose of this study is to determine the efficacy of single anastomoses sleeve jejunal bypass as a treatment for morbid obesity

in this study the investigators aim to test a new technique ( single anastomoses sleeve jejunal as a treatment for morbid obesity Which is a modification of Single anastomoses sleeve ileal bypass with short biliary limb ( about one third of the small intestine from the Duodeno-jejunal junction

Eligibility Criteria:
Inclusion Criteria:

* obese patients with BMI more than 40
* patients fit for laparoscopic surgery
* give approval to share in the study

Exclusion Criteria:

* patients refused to share in the study
* patients unfit for surgery
* patients aged less than 18 and older than 50
* patients with BMI less than 50
* patient with previous upper abdominal surgery either for obesity or other diseases
* patients with preoperative GERD clinically or by investigation
Acute Response to Exercise in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the joints, causing pain, edema, physical disability and poor quality of life. In addition, RA patients are at increased risk of developing cardiovascular disease (CVD) and premature death. The most effective pharmacological treatment is the use of biological agents that inhibit the action of specific substances, such as interleukin 6 (IL-6) and tumor necrosis factors (TNF). Physical exercise is considered a first-line non-pharmacological treatment in RA, improving inflammatory and metabolic profile, functional capacity, fatigue and preventing the onset of CVD. There is evidence that IL-6, when secreted as a result of exercise, brings several benefits. However, there is no study investigating the interaction between biological IL-6 blocking agents and exercise on metabolic responses, such as insulin sensitivity and glucose uptake, in patients with RA. To answer this question, adult women diagnosed with RA and healthy controls will be recruited for an acute session of exercise. RA patients will be divided into 2 groups, according to the pharmacological treatment (tocilizumab or anti-TNF). The acute responses of insulin sensitivity after an acute session of exercise will be assessed by the hyperinsulinemic euglycemic clamp, and the molecular pathways will be assessed by muscle biopsy and gene and protein expression analysis. Positron emission tomography-magnetic resonance imaging (PET/MRI) will be performed to quantify skeletal muscle glucose uptake.


Eligibility Criteria:
Inclusion Criteria:

* Adult women diagnosed with rheumatoid arthritis under pharmacological treatment, for at least 6 months, with a monoclonal antibody against the interleukin-6 receptor or TNF-alpha inhibitors;
* Stable dose of monoclonal antibody against the interleukin-6 receptor or TNF-alpha inhibitors in the previous 3 months;

Exclusion Criteria:

* Any physical limitation or disability that preclude exercise participation;
* Participation in a structured exercise program in the previous 12 months;
Pulsed Electromagnetic Field Versus Pulsed High Intensity Laser in the of Osteoprosis

Osteoporosis is the most prevalent metabolic bone disease. Although osteoporosis is widely considered to be much more prevalent in women approximately 39% of new osteoporotic fractures estimated to have occurred Worldwide in 2000 were in men. A number of studies investigate the effect of physical therapy modalities in treatment of osteoporosis. The use of pulsed electromagnetic field (PEMF) represents an attractive alternative for Osteoporosis. Previous studies suggested that pulsed electromagnetic field could be beneficial for increase bone mineral density in osteoporotic patients, but there is a lack of Knowledge about the comparison with pulsed high laser therapy.

Objectives: This randomized controlled study aims to investigate theEffect of Full-Body Pulsed Electromagnetic Field versus Pulsed High Intensity Laser Therapy in the Treatment of Men with Osteopenia or Osteoporosis Methods: Ninty male patients with osteopenia or osteoporosis will participate in this study, their age ranges between 30-60 years. They have BMD T-scores ≤ - 1.5. All patients will be randomized into one of three groups. Group one received PEMF and exercise (PEMF+EX), group two received HILT and exercise (HILT+EX) and group three will be treated by exercise alone (Ex). The exercise training program will include treadmill and aerobic exercises for hip and upper limb will be performed for 50 minutes.PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months. Dual-energy X-ray absorptiometry (DEXA) will assess Bone mineral density BMD (g/cm2), bone mineral content (BMC), T-Score and Z-Score at the lumbar spine, proximal femur and forearm region, bone markers (25-hydroxy Vit D , Total, undercarboxylated Ostocalcin, Parathyroid Hormone, Total and Ionized calcium and Alkaline Phosphatase (ALP), also will be measured. The assessment will be done at baseline, after treatment (12 weeks) and after 6 months as follow up. The data will be analyzed using repeated measures Analysis of variance (ANOVA) for comparison between pre-treatment and post treatment measurement intervals. One-way ANOVA is used to compare between each treatment interval in treatment groups at pre-test and post treatment measurement intervals. The level of significance is set at 0.05 for all tests.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a T-scores of ≤ #1.5, all patients received the same medical treatment for osteoporosis and the same average blood glucose level, sufficient ability to understand the nature and potential risks of the study.

Exclusion Criteria:

* Diabetes mellitus, ischemic heart disease, arrhythmia, uncontrolled thyroid disease, cardiac pacemaker, tuberculosis, neuropsychiatric disorders (dementia, cerebrovascular disease, alcohol abuse, severe depression, panic disorder, bipolar disorder, or psychosis), and malignancy.
Trans-Rectal Ultrasound-Guided (TRUS) Adverse Events

The goal of this study is to identify any side effects caused by the implanting of markers via the rectum. The investigators will also try to determine if any other factors (such as the position of the markers) influence the risk of side effects. The study procedures consist of two questionnaires:The first will be completed immediately after the marker implantation and the second questionnaire will be completed during your radiotherapy planning.

Precise localisation of target organs has become increasingly important with the routine use of steep dose gradients from conformal and intensity modulated radiotherapy. This is particularly challenging when soft tissue target organs, such as the prostate, displace relative to bony anatomy. Although novel imaging techniques are being developed for the direct visualisation of such soft tissue structures, contrast and image quality is currently limited. However, the use of radio-opaque intra-prostatic fiducial markers(IPM) during high dose radiotherapy has proven very effective in terms of improving accuracy, and decreasing toxicity.

Eligibility Criteria:
Inclusion Criteria:

* Have biopsy confirmed prostate cancer (any risk category)
* Have 3 intra-prostatic markers inserted at PMH prior to radiotherapy
* Be willing to provide written informed consent
* Be willing to complete the adverse event questionnaires
Level of Anxiety in Patients Undergoing Invasive Foot Surgery

In recent decades, preoperative anxiety has been studied by numerous authors from different medical-surgical specialties, however, there are no studies in the scientific literature on anxiety prior to surgical procedures in the area of minimally invasive foot surgery at the osteoarticular level.

The aim of the present study was to determine the level of preoperative anxiety and information using the Amsterdam Preoperative Anxiety and Information scale in patients undergoing minimally invasive podiatric surgery, as well as to determine the socio-demographic and surgical factors associated with preoperative anxiety.


Eligibility Criteria:
Inclusion Criteria:

* be over18 years old.
* ASA I and II (American Society of Anesthesiologists).
* autonomous capacity to fill out the surveys and participate in the study

Exclusion Criteria:

* mental and/or emotional disorders.
* incapacity to understand.
* people medicated with anxiolytics before the surgery.
* chronic pain in the foot and/or analgesic treatment for chronic pain.
* did not fulfill the postoperative recommendations.
* contraindication to the study's medical guideline.
Influence of Collagen Cone on the Outcomes of Immediate Dental Implant Placement in Esthetic Zone

Influence of Collagen Cone on the Outcomes of Immediate Dental Implant Placement in Esthetic zone

The present study will be performed to assess effect of collagen cone for bone width and length around immediate implants in esthetics zone.

Eligibility Criteria:
Inclusion Criteria:

- 1-Patients were free from any systemic disease as evidenced by Burket's oral medicine health history questionnaire 2- Each patient required extraction of a non-restorable premolar or anterior tooth maxilla and requested implant restoration.

3-All patients should not have any known contraindication to oral surgery. 4-Male or female with age range 30 - 50 years.
Cerebri Biofeedback Feasibility Trial

The purpose of this study is to investigate feasibility, usability, safety, efficacy, and tolerability of Cerebri biofeedback treatment for adults with episodic migraine.

In the study, the app-based biofeedback treatment Cerebri for migraines in adults will be tested. By using biofeedback, bodily signals that are thought to be associated with migraines, are measured. During the treatment, one sensor is attached on the shoulder to measure activity in the shoulder and neck muscles and one sensor is attached to the index finger to measure temperature and heart rate variability. By getting on-screen feedback on the phone, the user can learn techniques to reduce muscle tension, and increase finger temperature and heart rate variability. Reduced muscle tension, as well as increase in finger temperature and heart rate variability is a sign of relaxation and a deactivation of the nervous system, which can lead to fewer and less serious migraine attacks.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older, at the time of signing the informed consent
* Episodic migraines with or without aura diagnosed by a neurologist/physician per International Classification of Headache Disorders 3rd edition (ICHD-3).
* Having kept a headache diary with at least 80% adherence as part of routine clinical care in the last 28-days prior to inclusion.
* History of at least 4 and up to 14 days of migraines per 28-day period in the 3 months prior to screening, as recalled by the subject and confirmed in the clinical diary.
* At least three months of experience with smartphone and access to an iOS or Android phone at home.
* Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Onset of migraine before age 50 years.

Exclusion Criteria:

* Having a continuous background headache that never disappears completely.
* More than 14 days of headache (all types) per 28-day period.
* Subjects diagnosed with trigeminal autonomic cephalalgias and neuralgias.
* Subjects with secondary headache conditions.
* Subjects with headaches attributed by the treating neurologist/physician as being medication overuse headache according to the ICHD-3.
* Subject with pathologies that inhibit use of the device according to the instructions for use (e.g., blindness, deafness).
* Use of any concurrent preventive treatment (medications, meditation, physical therapy and psychotherapy as a headache treatment, acupuncture, etc.).
* Subjects who have previously failed three prophylactic pharmacological treatments.
* Subjects taking opioids (\>3 days per month) or barbiturates at the time of screening.
* Subject participates in another clinical investigation.
* Alcohol overuse according to ICD-10-CM Code F10.1 or illicit drug use.
* Subject who is unlikely to follow Clinical Investigation Plan or where treatment seems futile in the opinion of the Investigator or have demonstrated an inability to sufficiently adhere to headache diary entries (\<80%).
Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe

* To test the hypothesis that therapy with high dose statin provides endothelial superior benefit to the same cholesterol lowering with low-dose statin combined with ezetimibe.
* To test the hypothesis that therapy with high dose statin provides anti-inflammatory effect than the same reduction of cholesterol with low dose of statin plus ezetimibe

Randomized, double-blind, placebo-controlled study. Inclusion Criteria: Obese women with body mass index (BMI)\> 25 kg / m², aged 18 years and LDL-C\> 100 mg / dl For treatment with simvastatin 80 mg, the participant will receive two identical vials, each containing a simvastatin 40 mg. For treatment with the combination simvastatin 10 mg and ezetimibe 10 mg, the participant will receive two identical bottles, one bottle with simvastatin 10 mg, and another bottle with ezetimibe 10mg. In the control group, each participant will receive two identical bottles, each bottle containing inert tablets. Each group with 20 participants.

Dependent Variable (Final Primary Outcome): Percentage change vasodilation of brachial artery flow-mediated, after treatment for eight weeks.

Covariates: clinical, biochemical markers and ultrasound.

Eligibility Criteria:
Inclusion Criteria:

* Women with body mass index (BMI)\> 25 kg / m²
* Aged \> 18 years
* LDL-C\> 100 mg / dl

Exclusion Criteria:

* Previous use of statins, fibrates or ezetimibe
* Triglycerides\> 400 mg / dl
* Serum creatinine greater than 2.0 md / dl
* Elevated liver enzymes, more than one and half times the upper limit of normal
* Creatine kinase (CK) levels more than three times the upper limit of normal
* Pregnant
* Breast-feeding
* Heart failure
* Psychiatric disorders
* Hormone replacement therapy.
* The occurrence of recent onset within the last four weeks of treatment with beta-blockers, converting enzyme inhibitor or calcium channel blocker, the intervention should be undertaken after a period of at least four weeks of continuous use.
* Acute inflammatory processes in the last month, assessed by clinical history and physical examination (ear, throat, skin lesions or other inflammatory manifestations) as well as reports of chronic diseases such as collagen, or the occurrence of active tuberculosis in the last three months will be excluded from work.
A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of JNJ-49122944 in healthy male participants after a single intravenous (\[IV\] within a vein) dose administration.

This is a double-blind (neither the researchers nor the participants know what treatment the participant is receiving), randomized (study drug assigned by chance), placebo-controlled (an inactive substance; a pretend treatment \[with no drug in it\] that is compared in a clinical trial with a drug to test if the drug has a real effect), and single-center study. The study will consist of Screening Period (2 to 21 days prior to participants' dose administration), Double-blind Treatment Period (single dose of JNJ-49122944 or placebo on Day 1), and Safety Follow-up Period (4 to 7 days after discharge). The total duration of participation for each participant, including screening, will be up to approximately 4 weeks. Blood samples will be collected for assessment of pharmacokinetic parameters. Participants' safety will be monitored throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* Male participant, aged 18 to 55 inclusive
* Participant must have a body Mass Index (BMI) between 18 and 30 kilogram per square meter (kg/m\^2), inclusive, and body weight not less than 50 kg
* Participant must be deemed healthy on the basis of physical examination, medical history, laboratory tests, vital signs, and 12-lead electrocardiogram within protocol-defined parameters performed at screening and Day -1
* Participant agrees to protocol-defined use of effective contraception
* Participant should be non-nicotine user for 6 months prior to screening

Exclusion Criteria:

* Participants with current or history of clinically significant medical illness
* Participants with history of drug or alcohol abuse within 5 years
* Routine consumption of greater than 450 milligram (mg) of caffeine per day by the participant
* Participants with recent vaccination or acute illness
* Blood donation or major blood loss within 3 months prior to study drug administration by the participant
Effect of Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly

Maintenance of skeletal muscle mass is crucial during lifespan to retain health and functional autonomy. Sarcopenia, being the loss of muscle mass during aging, is a well-known phenomenon in the elderly and a major challenge viewed from an individual, and a socioeconomic point of view. Nevertheless, several studies have proved muscle tissue to be markedly affected by physical activity and nutritional interventions even at old age. Recently, a study in young individuals showed that an acute bout of easily tolerated low intensity exercise can prolong the muscle building effects of a milk protein intake compared to a non-exercised situation. Therefore, the major aim of the present project is to evaluate, whether a low intensity exercise regime in conjunction with milk protein supplementation can induce positive adaptations on parameters related to muscle size and function in elderly.

The study focuses on the acute muscle protein synthesis response to low intensity exercise and protein supplementation measured with stable isotope tracer techniques. It is hypothesized that light muscle activity can augment and prolong the effects of protein feeding.

If a light resistance exercise protocol as investigated in the present project can prove beneficial, elderly, frail elderly, and individuals undergoing rehabilitation can challenge sarcopenia in a new and tolerable way.


Eligibility Criteria:
Inclusion Criteria:

* Male
* \>65 year old
* Healthy
* BMI \<28

Exclusion Criteria:

* Smoker
* Type II diabetic
* Intake of medicine or supplements which will affect skeletal muscle protein synthesis
* Alcohol intake \>21 units/week.
* Frequent exercise or hard physical labor
Cilostazol Augmentation Study in Dementia

The purpose of this study is to examine the effects of cilostazol augmentation in mild to moderate Alzheimer disease patients with subcortical white matter hyperintensities (WMHI) treated by donepezil.

Dementia is the most disabling disease in the old age. The prevalence of dementia is 5-10% of the elders. AchEIs (donepezil, galantamine, rivastigmine) are used to treat mild to moderate dementia, but these drugs only relate to symptomatic improvement and the response rates are less than 30%.

Cilostazol is a cyclic adenosine monophosphate phosphodiesterase 3 inhibitor (PDE3I) and used as antiplatelet agent in subcortical vascular disease (WMHI). And it upregulates phosphorylation of cyclic adenosine monophosphate-pathway response element binding protein (CREB) which plays a crucial role in memory enhancement and synaptic plasticity related to neurodegeneration prevention.

The investigators will try cilostazol augmentation in dementia patients with WMHI receiving donepezil to see the addictive effects of cilostazol using cognitive tasks and PET imaging.


Eligibility Criteria:
Inclusion Criteria:

* Men/women over sixty years old
* Patients with slight and moderate dementia (MMSE score is over 10 under 26.)
* Patients with probable Alzheimer's disease according to the standard of NINCDS-ADRDA
* Patients accompanied with WMHI on Brain MRI (Fazeka's scale 1\~3)

Exclusion Criteria:

* Those who do not agree to the test in a written form
* Patients who accompany other diseases except cerebral atrophy or change of subcortical white matter due to Alzheimer's disease on brain MRI
* Patients who should not use Cilostazol (① patients with bleeding tendency ② patients with congestive heart failure ③ patients who have a medical history of hypersensitivity to this medicine or constituent of this medicine ④ those who use anticoagulant and clot buster)
* Patients who suffer from nerve diseases or mental diseases which have influence on cognitive function except Alzheimer's disease (for example, schizophrenia, severe depression, mental retardation and etc.)
* Patients who are suspected to have a personal history of drug addiction or alcoholism within recent 10 years
* Patients who have severe problems in eye sight or hearing so that it is impossible to conduct the test smoothly
* Patients who the researchers think are inappropriate for taking part in the test